The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of genomic assessment when selecting first-line therapy for chronic lymphocytic leukemia (CLL). Dr Jain highlights the value of the CLL fluorescence in situ hybridization (FISH) panel, immunoglobulin heavy chain variable region (IGHV) mutation status, and TP53 mutation testing for guiding individual treatment decisions for patients. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I would say, checking the, besides the, you know, the patient comorbidities and the tumor bulk and whatnot, I think the genomics of CLL is very important. From my standpoint, I think checking for three different things. First is the CLL FISH panel, IGHV status, and also assessing for TP53 mutation by a sequencing assay. I think those three tests, I think, are very important and crucial in assigning a risk category and also can help you decide what therapy you may want to consider for an individual patient...
So I would say, checking the, besides the, you know, the patient comorbidities and the tumor bulk and whatnot, I think the genomics of CLL is very important. From my standpoint, I think checking for three different things. First is the CLL FISH panel, IGHV status, and also assessing for TP53 mutation by a sequencing assay. I think those three tests, I think, are very important and crucial in assigning a risk category and also can help you decide what therapy you may want to consider for an individual patient. So I think those are, I would say, genomic assessments which should be done for all patients in CLL when you’re starting therapy for an individual patient. And I think if you have that information, obviously you have a patient in front of you, you know what their blood counts are, what their lymph node status is, maybe what their preference is, what their kidney function, renal function, cardiovascular complications have been or function. I think then you can decide how best to kind of approach an individual patient. So I think genomics is something we see sometimes are not done routinely for all patients with CLL. I think those are, I think it would be, as I said, IGHV status, FISH status, and TP53 mutation status are the most crucial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
